Allogene Therapeutics与Arbor Biotechnologies合作 - Allogene Therapeutics与Arbor Biotechnologies签署了全球基因编辑许可协议，将Arbor的CRISPR基因编辑技术应用于Allogene的下一代AlloCAR T平台，用于治疗自身免疫性疾病(AID)[1] - Allogene计划在2025年初启动首个自身免疫性疾病的AlloCAR T产品的临床试验[2] Arbor Biotechnologies介绍 - Arbor Biotechnologies是一家总部位于马萨诸塞州剑桥的下一代基因编辑公司，致力于利用CRISPR技术和先进的计算AI驱动发现，高通量筛选和强大的蛋白工程方法，开发新型基因药物[3]

Allogene Therapeutics, Inc. (ALLO) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALLO's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving avera ...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/ ...

公司财务报表重新核算 - Allogene Therapeutics宣布将重新核算2019年至2022年的财务报表，主要是由于在2020年12月成立亚洲Allogene Overland Biopharm合资企业所导致的非现金会计调整[1] - 重新核算的财务报表不会对公司的现金、现金等价物和可市场化投资、现金运营或业务运营产生影响，公司仍有足够的财务资源支持运营至2026年[2] - 公司计划在2024年3月14日或之前提交修订后的财务报表，并报告2023年第四季度和全年财务业绩，以确保信息的准确性和透明度[3]

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesday, February ...

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences in January and February. B. Riley Oncology ConferenceThursday, January 18, 202412:30PM PT/3:30PM ET Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceWednesday, February ...

医疗 - 生物医学和遗传学领域 - Allogene Therapeutics, Inc. (ALLO) 是医疗 - 生物医学和遗传学领域的一个有趣选择[1] - 医疗 - 生物医学和遗传学领域目前处于良好位置，Zacks Industry Rank 为 61[2] 公司表现 - Allogene 近期看起来也不错，过去一个月内，盈利预期有所提升[3] - 目前公司的 Zacks Rank 为 3 (Hold)，也是一个积极信号[4]

Partnership Will Utilize Foresight's Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene's ALPHA3 Trial SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products, and Foresight Diagnostics (Foresight), the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection today announced a st ...

Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic CAR T Large B-Cell Lymphoma (LBCL): Groundbreaking ALPHA3 Trial has Potential to Leapfrog Other CAR Ts and Embed Cemacabtagene Ansegedleucel (Cema-Cel, Previously ALLO-501A) in First Line (1L) Treatment in Community Cancer Centers Where Most Newly Diagnosed Patients Seek CareChronic Lymphocytic Leukemia (CLL): New ALPHA2 Cohort Designed to Address a Limitation of Auto ...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will host a conference call to preview its 2024 Platform Vision focused on redefining the future of CAR T by leveraging the unique attributes of allogeneic CAR T products. The 2024 Platform Vision conference call will be hosted on Thursday, January 4, 2024, at 2 ...